This paper explores the relationship between investing in pharmaceutical manufacturing risk reduction and meeting business objectives.
Lawrence Liberti
Advertisement
Lawrence Liberti, PhD, BPharm, RAC, is Director, The University of Southern California (USC) DK Kim International Center for Regulatory Science
Articles by Lawrence Liberti
Advertisement
Latest Updated Articles
ICH Q9: Attaining a Quality-Business Synergy through Quality Risk Management, ROI Analysis, and Highly Capable FacilitiesPublished: January 15th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
2
PharmTech Weekly News Roundup – Week of November 3, 2025
3
How AI, Machine Learning, and Large Language Models Enhance Bioanalysis
4
AAPS PharmSci 360 2025: Trends in Bioanalysis
5
